Bayer’s present owners will remain the owners of assets transferred to Lanxess. The arrangement, besides convenience, is also expected to continue the offshoot’s development in line with its shareholders’ expectations.

CEO designate of Lanxess, Dr Axel C. Heitmann, pleased with Bayer’s decision, stressed the need to instil confidence in the company’s new stockholders and prove it is worth their investment.